Spectradyne has commercialized a revolutionary method of measuring sub-micron nanoparticles. Applications include characterizing nanomedicine delivery systems, the measurement of protein aggregation in the drug development industry, virology and in consumer product quality control. Fraikin developed the initial NPA technology during his PhD thesis work at UC Santa Barbara in Dr. He has worked in cancer cell biology and biochemistry, and at InDevR led prototyping efforts for a microfluidics-based molecular diagnostic platform. At Spectradyne, Dr Fraikin previously led the development of instrument fluidics, software, and system integration.